Currently, yes semaglutide has proven cardiovascular benefit from the SELECT trial (2023), which demonstrated significant reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with obesity and established heart disease
It might affect absorption, Wojeck says
Without these habits, weight regain is possible
Failure to include these warnings on the drug label leaves Novo Nordisk and other GLP-1 agonist manufacturers open to liability for victims damages and suffering
This targeted response improves metabolic efficiency and glycemic stability
Our team is dedicated to guiding clients through this process, ensuring they achieve their health and wellness goals safely and effectively